Business

UCB acquires Candid Therapeutics for USD 2.2b to expand T-cell engager immunology platform

Edited by Robert McTiernan··3 min read

Belgium-based UCB (Euronext Brussels: UCB) has agreed to acquire San Diego-based Candid Therapeutics in a transaction valued at up to USD 2.2 billion, adding a clinical-stage bispecific T-cell engager platform to its immunology portfolio. The UCB Candid Therapeutics acquisition centers on cizutamig, a BCMAxCD3 bispecific antibody targeting plasma cell depletion across multiple autoimmune indications, and extends UCB's stated strategy of building a multi-target B-cell depleting franchise through inorganic investment.

Under the deal terms, UCB will pay USD 2 billion in upfront payments, with up to USD 200 million in potential future milestone payments, bringing the total transaction value to USD 2.2 billion. The press release does not break down the milestone payments into development, regulatory, or commercial sub-categories. The transaction is structured as a full company acquisition and remains subject to antitrust clearance and other customary closing conditions, with completion expected by end of Q2 or early Q3 2026.

Cizutamig and the UCB Immunology Pipeline T-Cell Engager Strategy

Candid was established in September 2024 with a USD 340 million Series A round and a pipeline sourced primarily from China-based partners, including EpimAb Biotherapeutics and Genor Biopharma. The company is focused on T-cell engager (TCE) antibodies designed to selectively deplete pathogenic B lymphocyte populations, reflecting clinical evidence that B cells are central drivers of autoimmune disease through autoantibody production, antigen presentation, and cytokine signaling.

Selective B-cell depletion has shown high efficacy in refractory autoimmune conditions, and Candid’s platform is designed to redirect T-cell cytotoxicity toward defined B-cell subsets to enable deeper and more durable disease control.

The lead asset, cizutamig, is a bispecific antibody targeting B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells. The molecule is engineered to enhance targeted cytotoxicity while limiting cytokine release, a design approach intended to mitigate safety challenges associated with earlier T-cell engager formats. Cizutamig has been evaluated in more than 100 patients across oncology and autoimmune settings and is currently enrolling across more than 10 autoimmune indications.

Candid’s broader pipeline was assembled through a three-way merger with Vignette Bio and TRC 2004, integrating two clinical-stage bispecific programs: CND106, a BCMAxCD3 antibody licensed ex-China from EpimAb, and CND261, a CD20xCD3 antibody licensed ex-China from Genor. Both assets have completed Phase I dose escalation studies in a combined cohort of more than 130 oncology patients and are being advanced into autoimmune indications.

The AllSci BriefSystematic R&D and deal news. Daily.

Beyond these programs, Candid is developing additional multi-specific T-cell engagers using a modular, multi-antigen targeting strategy aimed at more complete elimination of pathogenic B-cell subsets. The company frames this approach as “immune reset” therapeutics, targeting sustained suppression or elimination of disease-driving immune cells rather than chronic symptom management. A preclinical tri-specific TCE sourced from WuXi Biologics carries global rights, while lead clinical assets remain subject to ex-China licensing structures.

The deal context

The UCB Candid Therapeutics acquisition follows a prior UCB transaction with Antengene, in which UCB secured a worldwide exclusive license for ATG-201, a CD19xCD3 bispecific T-cell engager for autoimmune diseases, with an upfront and near-term payment of USD 80 million and potential milestones bringing the total to approximately USD 1.18 billion. The Antengene transaction is explicitly cited in the Candid press release as a companion investment, with UCB describing the two deals as complementary coverage of multiple B-cell targets through differentiated mechanisms. Together, the two acquisitions position UCB with BCMA-directed and CD19-directed T-cell engager assets operating across overlapping but distinct B-cell subsets.

Separately, Cullinan Therapeutics has pursued a structurally comparable strategy in the same target space, licensing velinotamig, a BCMAxCD3 bispecific T-cell engager for autoimmune indications, from Genrix Biosciences in a deal valued at up to approximately USD 712 million. That transaction, which also included a CD19xCD3 asset, reflects independent validation of the BCMA-directed T-cell engager thesis in autoimmune disease, the same mechanistic rationale underlying cizutamig's clinical development program.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article